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Abstract Hemostasis is a complex process in which abnormalities can cause shifts toward
prothrombotic or prohemorrhagic states resulting in thrombosis or bleeding, respec-
tively. Several coagulation tests may be required to characterize these defects but may
yet not always reflect a patient’s true hemostatic capacity. Thus, global coagulation
tests aiming to simulate the coagulation process in vitro instead of measuring single
components thereof are certainly of interest to assess prothrombotic or prohemor-
rhagic tendencies. This review describes the development and application of global
coagulation tests, concentrating on themore widely usedmethods of viscoelastometry
and thrombin generation. A focus is placed on conditions characterized by simulta-
neous changes of various components of hemostasis, such as anticoagulant therapy or
hormone-induced coagulopathy, in which global coagulation tests are especially
promising. If the key challenges of standardization and automation of these tests
are solved, as is the case with automated thrombogram or clot waveform analysis,
global coagulation assays will play an important role in the future of laboratory
diagnostics of hemostasis and thrombosis.
Zusammenfassung Die Hämostase ist ein komplexer Prozess, bei dem Anomalien prothrombotische oder
prohämorrhagische Zustände auslösen können, die zu einer Thrombose oder Blutung
führen. Die Diagnose solcher Störungen kann mehrere Labortests erforderlich machen,
die dennoch nicht immer die tatsächliche Hämostasekapazität eines Patienten wider-
spiegeln. Daher zielen Globalteste der Gerinnung darauf ab, den Gerinnungsprozess in
vitro zu simulieren, anstatt einzelne daran beteiligte Komponenten zu messen. Diese
Übersichtsarbeit beschreibt Entwicklung und Einsatz dieser Globalteste, wobei sie sich auf
die verbreiteten Methoden der Viskoelastometrie und Thrombingenerierung konzen-
triert. Im Fokus stehen Zustände mit gleichzeitigen Veränderungen verschiedener
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Global coagulation tests aim at measuring the clotting sys-
tem in its entirety, instead of focusing on an individual
protein or pathway.1,2 The definition of “global assay” is
difficult to delimit. It could be said that they are function
tests of the hemostatic system, where assay conditions are
chosen to reflect the interaction of all its components in the
same way as they would in vivo. Current guidelines incorpo-
rate the use of global coagulation tests especially in the
management of acute hemorrhage.3,4 Various approaches
for global coagulation testing are available, among which the
following examples will be briefly introduced below: viscoe-
lastometric testing, clot waveform analysis (CWA), thrombin
generation assay (TGA), and sonic estimation of elasticity via
resonance (SEER).
Viscoelastometric coagulation testing by forced oscillation
rheometry was first presented in 1948.5 By capturing clot
formation, clot elasticity development, and fibrinolysis in real
time, it mainly reflects the coagulation process in terms of
maximalfibrin clot formation.6 It has becomeamethodwith a
broader range of applications since the 1970s as it is conve-
nient as a point-of-care test.7,8 In the 1980s the method was
used for monitoring hemostasis during liver and cardiac
surgery.9,10 The currently most widely applied test systems
are thromboelastography (TEG) and rotational thromboelas-
tometry (TEM). A recent variant of TEG, TEG-6s, applies
resonance-frequency viscoelasticity measurements and pre-
mixed disposable multichannel microfluidic cartridges to
bypass the limitations of prior models. This point-of-care
device can provide the measurements on whole blood and
eliminates the need for centrifugation, which is a gain of time
and also reflects the interaction between coagulation path-
ways and cellular blood components.11 The Sonoclot is also
considered a viscoelastrometric coagulation test and consists
of a device which measures the changing impedance to
movement imposed by the developing clot on a small probe
vibrating at an ultrasonic frequency in a clotting blood sam-
ple.12 Not so far away from the viscoelastometric methods,
sonorheometry is a novel method, commercialized under the
brandnameHemosonicsQuantra (Diagnostica Stago), that has
recently been authorized on the European and U.S. markets.
The technology is based on the utilization of high-frequency
ultrasoundpulses toquantify the shearmodulus (i.e., stiffness)
of a blood sample during the process of coagulation. The shear
modulus is a parameter that describes the elastic properties of
a solid material.13,14
CWA differs from other global coagulation assays as it is
an enhanced version of a global clotting time. First described
in 1997, it makes use of photo-optical measurement of the
clotting-induced change in transmittance/absorbance over
time.15 Initially it was developed to detect and to monitor
disseminated intravascular coagulopathy (DIC). It has been
proven to be a highly specific and sensitive assessment tool
and is therefore recommended by the guidelines for diagno-
sis and treatment of DIC.16,17 Some authors made use of the
CWA to assess coagulation abnormalities in septic patients
and suggested that CWA even outperforms standard inflam-
mation parameters in the determination of the severity and
prognosis of sepsis.18 However, CWA is not very sensitive
toward slight thrombogenic states, like hormone-induced
coagulopathy. An evolution of this test led to the FibWave, a
new method based on the same principle as CWA, which
seems to be more sensitive toward these slight changes in
coagulation factor levels.19
The measurement of in vitro thrombin generation in
whole blood and plasma was first described in 1953.20,21
The initially time-consumingmethodwas thenmodified and
refined over the following decades leading to several throm-
bin-generation platforms.22,23 In general, they evaluate in
vitro thrombin generation in a sample of platelet-poor
plasma after coagulation activation by tissue factor (TF)
and phospholipids, continuously monitoring the reaction
of thrombin generation by means of a thrombin-specific
fluorogenic substrate (or eventually a chromogenic one).
Some TGA variants may also be performed in platelet-rich
plasma and even in whole blood and may therefore reflect
the interplay of these cellular components and the coagula-
tion proteins.24 At this time, TGA is recommended for the
assessment of activated protein C (APC) resistance.25,26
Indeed, by adding exogenous APC, this assay is capable of
detecting changes in hemostasis induced by the hormonal
status of women (i.e., during pregnancy, on hormonal con-
traceptive or hormonal replacement therapy [HRT] during
menopause). Moreover, it is also sensitive to thrombophilia
such as factor V Leiden (FVL) mutation, prothrombin
20210G>A mutation, or protein S (PS) deficiency.27 There-
fore, this TGA variant, termed endogenous thrombin poten-
tial (ETP)-based APC resistance assay, may provide sufficient
information to screen several losses or gains of function
which increase the risk of thrombosis. (The ETP-parameter,
which represents the amount of thrombin generated after in
vitro activation of coagulation, is one of the five TGA-param-
eters.) Recently, a validated ETP-based APC resistance assay
and a harmonized scale have been proposed to consider the
use of this test in clinical routine in view of its screening
potential.27 The most widely used TGA method, the calibrat-
ed automated thrombogram (CT), is performed in a 96-well
Koagulopathie, bei denen der Einsatz von Globaltesten besonders vielversprechend ist.
Falls es, wie beim Automated Thrombogram oder der Clot Waveform Analyse, gelingt, die
zentralen Herausforderungen der Standardisierung und Automatisierung zu lösen,
werden Globalteste der Gerinnung eine wichtige Rolle in der Zukunft der Labordiagnostik
von Hämostase und Thrombose spielen.
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plate, and it requires specialized technologists. This has
resulted in a low implementation of this technique in routine
laboratories but recent evolutions of TGA platforms have led
to the advent of an automated system, the ST-Genesia, which
should resolve this issue.28
Assessment of Prothrombotic Abnormalities and
Complex Coagulation Disorders
Global coagulation times, while being sensitive in the screen-
ing for deficiencies of coagulation factors, utilize high
amounts of activators to initiate clotting, which substantially
reduces their sensitivity to detect small quantities of coagu-
lation-activating factors in the circulation. Nevertheless,
several studies have shown an association between a short-
ened activated partial thromboplastin time (aPTT) and the
riskof recurrent venous thromboembolism (VTE).29–31How-
ever, activity levels of the determinants of the aPTT, coagu-
lation factors VIII, IX, and XI, have been shown to be better
predictors of recurrent VTE,31 and no predictive value of the
aPTT has been found regarding the thrombotic risk associat-
ed with trauma, surgery, or cancer.32–34 CWA takes into
account not only the clotting time but also curve changes
of the optical density. This further developed variant of the
aPTT has been predominantly used to investigate abnormal-
ities in complex coagulation disorders, and certain character-
istics of CWA parameters have been shown to be predictors
of hypercoagulability in sepsis or of VTE in patientswith liver
cirrhosis.35–37
Viscoelastometric methods, including TEG, TEM, and
Sonoclot, have found widespread use to guide the therapy
with blood products in patients with active bleeding.
Changes of parameters of both tests, especially an increase
of themaximum amplitude (TEG) or maximum clot firmness
(TEM), have been suggested to be indicative of a hypercoag-
ulable state.38,39 The ability of viscoelastometric testing to
predict clinical thromboembolic events was recently ana-
lyzed in a large meta-analysis that included 41 studies with
more than 10,000 patients, including predominantly trauma
patients, patients undergoing elective surgery, patients with
malignancies, and patients with a history of arterial or
venous thrombosis. This meta-analysis reported a moderate
ability of TEG and TEM to discriminatebetween patientswho
developed thromboembolism and those who did not, with a
pooled sensitivity of 56%, a specificity of 76%, and a diagnos-
tic odds ratio of 3.6.40 Further studies reported an association
between changes of TEG or TEMparameters and situations of
increased thrombotic risk, such as cancer41,42 or pregnan-
cy,43–45 without investigating potential clinical manifesta-
tions of a hypercoagulable state. Initial research found the
Sonoclot of some interest in cardiac and liver surgeries as
well as in the assessment of hypercoagulable states.46–48
However, the Sonoclot has not been widely adopted and
there is a paucity of data regarding the reference ranges that
are needed to guide clinical decisions.49 There is also a
paucity of studies that directly compare parameters of
viscoelastometric testing with established molecular bio-
markers of coagulation activation to predict thromboembol-
ic events. However, in complex coagulation disorders
viscoelastometric tests have the advantage of considering
changes of cellular and fibrinolytic components, which are
not captured by conventional plasmatic coagulation tests.
While prolonged clotting times and reduced plasma levels of
procoagulant factors suggest a hypocoagulable state in sepsis
or liver disease, viscoelastometric parameters can be normal
or even indicative for a hypercoagulable state, and might
thereby better reflect a shift of the hemostatic balance in
these coagulation disorders.50–52 It has been shown that in
septic patientswith prolonged prothrombin timebut normal
or hypercoagulable parameters of viscoelastometric testing,
invasive procedures are not associated with an increased
bleeding risk.53,54 This is also reflected by the discordance
that has been observed between international normalized
ratio and TEG R times in previous studies.55 Also, both hyper-
or hypofibrinolysis can be detected by viscoelastometric
testing in trauma patients and patients with sepsis, DIC, or
liver disease.56–59 However, appropriate methodologies and
reagents are required to assess these hypofibrinolytic
states.60
The relationship between in vitro thrombin generation
and thrombotic risk was investigated in several studies, in
which an association between the ETP and other thrombin
generation parameters and the risk of recurrent VTE was
observed.61–63 An increased ETP in platelet-rich plasma was
reported in young stroke patients.64 In another study, an
increase of ETP and thrombin peak height was associated
with the risk of acute ischemic stroke but not with coronary
heart disease in elderly patients.65 Among the classical
thrombophilia risk factors, deficiencies of antithrombin
(AT), PS (in a modified version of the assay in which throm-
bomodulin is added), and the FVL and prothrombin
20210G>A mutations are associated with an increased
ETP.66–69 An increased ETP has also been observed in the
presence of acquired risk factors of thrombosis, including
cancer, the use of combined hormonal contraceptives
(CHCs), and pregnancy.70,71 However, a correlation between
the increase of in vitro thrombin generation and indirect
markers of in vivo thrombin formation was not observed in
these studies. The TGA has been found to be sensitive to
various direct-acting agents of coagulation in the analyzed
plasma including microparticles, TF, and lipopolysacchar-
ides.72–74 By adding an amount of exogenous APC, the TGA
can be used to assess the functionality of the anticoagulant
protein C (PC) pathway. Thrombin generation tests used in
this variant are capable of detecting hereditary APC resis-
tance (e.g., FVL mutation) as well as acquired forms of
impaired APC sensitivity (e.g., the one caused by ligands of
estrogen receptors such as the estrogen components of CHCs
and other drugs).75–77
Assessment of Hormone-Induced Coagulopathy
CHCs and postmenopausal HRTs are widely used around the
world. More than 200 million women aged between 14 and
60 years are undergoing one of these treatments, which are
associated with a risk of thrombosis that affects nearly
100,000 women each year.78–80 CHCs were first introduced
on the market in the early 1960s and have been extensively
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studied since then.81,82 Overall, it has been revealed that the
effect of CHCs on hemostasis depends on the type and dose of
estrogen, and the type and dose of the associated progesto-
gen, which is clinically reflected by the estimated risk of VTE
depending on the different generations of CHCs (►Table 1).83
Although the thrombogenicity of CHCs is well known,
current practice does not regularly include a laboratory
screening to assess a woman’s individual risk of VTE before
initiation of CHC use or HRT. While the prescribing physi-
cian’s decision considers the patient’s wish and her family
history of thrombosis, thrombophilia risk factors (e.g., the
FVL and prothrombin 20210G>A mutations, and deficien-
cies of AT, PC, and PS) are generally not taken into account,
although they lead to a higher baseline risk of VTE.84,85
Among these genetic risk factors, FVL and prothrombin
20210G>A are the most frequent and are present in 3 to
15% of the Caucasian population.86 The risk of a first VTE
event is four- to eightfold higher in heterozygous carriers
while it may reach a relative risk of 30 to 80 in homozygous
carriers.87–90When combinedwith the use of CHCs or HRT, it
affects the coagulation cascade synergistically leading to a
major risk of thrombosis during the first year of use.85,91–96
For example, if it is reported that the relative risk of throm-
bosis in heterozygous FVL carriers is approximately 4, in
women on third-generation CHCs, it will be approximately
3.5 and the combination of these two risk factors leads to a
relative risk of 45, revealing a synergistic index of more than
3.97
Overall, CHCs and HRTs induce changes in numerous
hemostasis variables, depending on their estrogenic and
progestin compounds. On one hand, they impact positively
the procoagulant pathways (i.e., increased levels of fibrino-
gen, prothrombin, factors VII, VIII, and X) and, on the other
hand, they impact negatively the anticoagulant pathways
(i.e., decreased levels of AT, PS, and TF pathway inhibitors).
These changes also lead to an acquired APC resistance, which
is an independent risk factor of VTE.78,98,99 Today, a complete
thrombophilia screening requires several coagulation tests
which canmake the interpretation of the results difficult and
expensive. Even if the changes of coagulation factor levels
induced by CHCs do not exceed their respective normal
ranges, an increased thrombogenicity is the result of a
synergistic effect of these changes and global tests are able
to reveal these synergistic effects. It should be noted that
changes are more pronounced with third- and fourth-gener-
ation CHCs in comparison to second-generation CHC, which
corresponds to the clinical risk of VTE observed in epidemi-
ological studies.92,100,101Moreover, the endpoint of clotting-
time-based assays corresponds to the beginning of thrombin
generation, which means that the conventional tests inform
only on the initiation phase of coagulation but not on the
hemostatic capacity in terms of clot formation and maxi-
mum thrombin generation.102 Therefore, a global coagula-
tion assaywould seemmore appropriate to assess the overall
thrombotic risk in women on CHC or HRT treatment. Such
assessment could be informative before the initiation of any
hormonal therapy or to ensure a longitudinal monitoring
since interindividual variability in response to the treatment
has been reported, corresponding to the interindividual
variability in the metabolism of ethinylestradiol.103
TEG has been assessed in women on CHCs. In the study of
Sucker et al the influence of oral contraception on TEM was
investigated in a small group of women and significant
changes of several parameters including shorter clot forma-
tion time (upon extrinsic activation), broader maximum clot
firmness (upon intrinsic activation), and broader a-angle
(upon extrinsic activation) were observed.104 However, the
study size was limited and therefore, further investigation is
required before confirming that the TEMmay be appropriate
to assess hemostasis changes induced by CHCs. Thrombin-
generation testing has been found to be very sensitive toward
hemostasis changes induced by CHCs. A correlation between
the increase of the normalized APC sensitivity ratio (nAPCsr,
the measure of the ETP-based APC resistance) and the risk of
VTE has been shown in different studies demonstrating the
high potential of ETP-based APC resistance testing for the
prediction of VTE riskboth in the presence and absence of the
FVLmutation.27,105,106 In addition, the extent of the increase
of the nAPCsr has been found to be associated with the VTE
risk observed in epidemiological studies (►Fig. 1).107 Inter-
estingly, the nAPCsr and the relative risk of VTE in patients
with heterozygous FVL and in women on third-generation
CHCs are similar suggesting a close association between this
test and the relative risk of VTE. Also, the combination of
estradiol valerate with dienogest, which demonstrated the
lowest VTE risk, even when compared with levonorgestrel-
containing products, demonstrated a lower nAPCsr, as
depicted in ►Fig. 1.107 Thus, identification of women with
a higher thrombotic risk before the initiation of hormonal
therapy would allow two opportunities: first, to suspect an
underlying genetic disorder and thus to guide toward amore
specific diagnostic test and life-long prevention strategy,
and second, to prescribe the safest hormonal therapy accord-
ing to the patient’s clinical status. In addition, it would
Table 1 Risk of developing venous thromboembolism (VTE) in women using combined hormonal contraceptives (CHCs), adapted
from European Medicines Agency83
Generation of used CHC (progestin and derivative) VTE risk/year
No CHC use and no pregnancy 2 out of 10,000 women
Second (levonorgestrel, norethisterone, or norgestimate) 5–7 out of 10,000 women
Third (desogestrel or gestodene) 9–12 out of 10,000 women
Fourth (drospirenone) 9–12 out of 10,000 women
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support the implementation of risk minimization strategies
to reduce the life-long risk of VTE.
Assessment of Prohemorrhagic Tendencies
Both commonly applied viscoelastometric tests (TEG and
TEM) have been shown to be eligible for the detection of
coagulopathy and hemorrhage in trauma, surgery, and be-
yond that, guiding hemostatic therapy in adult and pediatric
patients.108–110 TEG has been demonstrated to improve the
treatment of acute hemorrhage in terms of a decreased
amount of transfusions and lowered costs.111 In vitro throm-
bin generation measurement is indicative for hypercoagula-
bility but might also become an important tool in managing
hemorrhage.112 It has been proven useful in the treatment of
hemophilia patients, especially when bypassing agents are
applied.113,114 In vitro thrombin generation has been shown
to be reduced in hemophilia A and B as well as in rare
congenital coagulation factor deficiencies includingdeficien-
cies of factor II, V, VII, X, XI, and XII.115An ETP below20% of its
normal value was associated with an increased risk of
bleeding in patients with hemophilia A or B.116 While factor
XIII (FXIII) deficiency did not affect thrombin generation,
some data may reveal that this may reduce the maximum
amplitude of the TEG.117 However, these data were obtained
using commercially available plasma from patients with
severe FXIII deficiency. Patients with mild to moderate FXIII
deficiency may not present with the same extent of changes
in TEG. Further data are needed to confirm the usefulness of
TEG in this context.
Factor replacement therapy in hemophilia patients with
and without inhibitors can also be monitored by thrombin
generation tests.118–120 Treatment monitoring and estima-
tion of bleeding tendency in hemophilia patients is also
another possible application of CWA.121,122 TGA might give
more information about thehemostatic capacity in total than
viscoelastometric testing as it looks beyond fibrin clot for-
mation. TEG and TEM have also been shown to be useful in
the management of patients with acquired forms of coagul-
opathy in major surgery.123
Assessment of Anticoagulant Therapies
A monitoring of the anticoagulant activity of direct oral
anticoagulants (DOACs) is generally not necessary but a point
estimation could be useful in vulnerable patients.124 Specific
laboratory tests have been pointed out as the more appro-
priate assays since they provide results expressed in ng/mL,
which corresponds to the unit used for the definition of the
tentative thresholds associated with bleeding risks or partic-
ular interventions (i.e., administration of antidote, eligibility
for thrombolysis, etc.).125–130However, these thresholds are,
for some of them, arbitrary, based on expert’s opinions and
may not reflect the intrinsic anticoagulant activity of DOACs.
Fig. 1 Synthesis of studies from 1997 to 2019 investigating the impact of oral contraceptives on the APC resistance, when expressed as nAPCsr
(absolute). Left Y-axis represents nAPCsr in absolute values. Right Y-axis represents the estimated incidence of venous thromboembolism issued
from the EMA assessment report.83 The estimated rates of VTE is 2 per 10,000 women-years in non-OC users; 5 to 7 in second-generation CHC
users; 9 to 12 in third-generation, drospirenone and cyproterone acetate CHC users; and around 7 in dienogest CHC users (data from the INAS-
SCORE study; direct comparison should not be made since in this study the combination of ethinylestradiol with levonorgestrel was 8.8/10,000
women-years). The lower risk of estradiol valerate plus dienogest compared with other CHCs including ethinylestradiol plus levonorgestrel
observed in the INAS-SCORE study is associated with a lower impact of this combination on the nAPCsr. Estetrol (E4) plus drospirenone appears to
have a low impact on nAPCsr suggesting that the risk is linked to the estrogenic component rather than to the progestin.107 2G, second-
generation combined oral contraceptive; 3G, third-generation combined oral contraceptive; CHC, combined hormonal contraceptive; CPA,
cyproterone acetate; DNG, dienogest; DRSP, drospirenone; EE, ethinylestradiol; E2, 17β-estradiol; E2V, estradiol valerate; EMA, European
Medicines Agency; ETP, endogenous thrombin potential; nAPCsr, normalized activated protein C sensitivity ratio; NOMAC, nomegestrol acetate;
OC, oral contraceptive; VTE, venous thromboembolism.
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For example, the threshold proposed for the administration
of reversal agents does not consider the different pharmaco-
dynamic profiles of the drugs.126Namely, it has already been
demonstrated that 30 or 50 ng/mL of rivaroxaban does not
have the same anticoagulant activity as the same amount of
apixaban, betrixaban, or edoxaban (►Fig. 2).131–135 This is
also reflected by the necessity of adapting the methodology
of specific chromogenic anti-Xa assays depending on the
drug used.135 Consequently, these tests do not reflect the in
vivo intensity of anticoagulant activity. TGA, viscoelastomet-
ric assays (TEG, TEM, ClotPro) and more recently SEER
sonorheometry are considered as global assays of hemostatic
function.121,124 They are able to measure the kinetics of
thrombin or fibrin formation over time in clotting plasma.102
These assays provide more information than simple clotting
time tests and are of interest for the detection of coagulation
abnormalities.136 Nevertheless, in the setting of anticoagu-
lant therapy,most of these global assays often lack sensitivity
or if they aremodified to become specific, i.e., by the addition
of particular triggering agents, they no longer provide a
global assessment as this is the case with the ecarin TEG
for specific dabigatran assessment. Indeed, they only focus
on a particular pathway or factor. Activation of coagulation
factors of the common pathway by snake venom or addition
of direct catalytic enzymes like activated factor X or throm-
bin is frequent in this specific testing, and therefore retro-
activation pathways or contribution of upstream coagulation
factors is lacking. However, this may help to discriminate an
underlying coagulopathy not secondary to the effect of the
anticoagulant therapy (i.e., acquired hemophilia) that could
also result in bleeding.
Several in vitro and ex vivo studies have already demon-
strated the potential of TGA for the assessment of the effect of
DOACs and the monitoring of reversal therapies without
modifying the inducers or the reagents, meaning that the
test keeps its capacity to assess the coagulation in its global-
ity.130–133,137–141 Preliminary observations showed that
thrombin generation testing is affected by all anticoagulant
drugs and therefore it could be the candidate as-
say.140,142–146 The test has been found to be very sensitive
to all kinds of anticoagulants130–133,138,143,147 and may
better represent the interindividual response than just ex-
ploring plasma concentrations.140 In addition to considering
the interindividual response to an antithrombotic drug,
thrombin generation testing is also able to explore in more
detail the impact of anticoagulants on the coagulation pro-
cess. Namely, depending on the type ofdrug, different studies
confirmed that the fingerprint of in vivo thrombin genera-
tion differs, revealing the different pharmacodynamics of the
drugs (►Fig. 2).141,143,147,148 This is of particular importance
since bleeding or thrombosis has been reported within the
“on-therapy” range, demonstrating that the drug level alone
may not be sufficient to identify those who are more at
risk.149 However, further investigation on patients who
bleed or who have recurrent thrombosis while on a fixed
dose of anticoagulants is needed to show the benefit of in
vitro thrombin generation testing and provide cut-offs for
bleeding and thrombotic complications. The TGA has also
been reported to be an informative tool to document on
antidote administration in polytrauma models with direct
implication for patient care.150 This is particularly important
as it may help in adjusting the dose of prothrombin complex
concentrate to administer.151
Limitations and Open Questions
Despite their advantages, global coagulation assays still
remain experimental in vitro models of hemostasis that
only aim to mimic all important aspects of the physiological
(and pathological) clotting process. To date, none of the
existing global assays has been shown to actually involve
all components of hemostasis. For example, the major short-
coming of the viscoelastometric methods TEG and TEM are
their insensitivity to platelet dysfunction and von Wille-
brand factor deficiency. FXIII, which is also not assessed in
the global clotting time assays, is not adequately reflected,
too.123 TGAs can be modified to diagnose defects in fibrino-
gen, fibrinolysis, and the PC system.75 However, these var-
iations detract from the paradigm of a global coagulation
assay and may dilute their advantages. No coagulation test
will be able to predict an increased risk of bleeding or
Fig. 2 Thrombin-generation profiles of different direct oral anticoagulants (DOACs) at thresholds used for antidote administration in case of
bleeding or urgent surgery and to allow thrombolysis (i.e., 30, 50, or 100 ng/mL).
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thrombosis due to factors affecting the vasculature or other
tissues as well as compromised cellular or plasmatic coagu-
lation. If the origin of a bleeding is not initially caused by
compromised hemostasis, all global coagulation tests can be
perfectly normal.
One particular problem of global coagulation assays is
preanalytics as their high sensitivity makes them vulnerable
to inaccuracies and variables of sample collection and prep-
aration.152,153 On the other hand, viscoelastometric testing
lacks the sensitivity to detect patients with thrombophilic
defects, which is essential for its use, e.g., in the screening of
women before the initiation of a hormonal therapy.154,155
Viscoelastometric assays also have a poor to zero correlation
with platelet related/associated defects like Glanzmann’s
thrombasthenia or von Willebrand disease. On a more
technical side, especially with point-of-care tests, in which
whole blood is investigated, standardization is often lacking.
There are also difficulties for laboratories to verify the
performance of these methods. Another significant limita-
tion of the viscoelastometric assays is the requirement for
stabilized surfaces to avoid false pin/cup movements. Cur-
rent research is ongoing to developmobile viscoelastometric
measuring devices. The lack of standardization between the
different technologies on themarket23 also limits the routine
clinical use of TGA, which has been addressed in several
studies.152,156,157 Recently, the ST-Genesia, a fully automat-
ed thrombin generation analyzer, was reported to provide
enhanced reproducibility compared with the CT. This new
analyzer also offers a normalization of TGA parameters with
the use of CE-marked reference plasma, calibrators, controls,
and reagents that minimize the interlaboratory variabili-
ty.28,158,159 While TEG and TEM have the major advantage of
being suitable to be used point-of-care, the main disadvan-
tage of thrombin generation tests is their comparably long
turnaround time, which may be reduced by testing whole
blood.160
In the assessment of the individual prothrombotic or
prohemorrhagic tendency, global coagulation tests have to
compete with tests that detect specific defects, such as
deficiencies of coagulation factors or inhibitors, and in the
assessment of hypercoagulability also with tests that mea-
sure specific markers of coagulation activation. In the field
of complex coagulation disorders these alternative
approaches have the disadvantages that they cannot be
performed point-of-care, and that possibly a lot of different
specific tests need to be performed to get the same infor-
mation as with a global point-of-care assay, tests that
require more blood sampling and a more specialized labo-
ratory with a broad range of methods. Furthermore, a
complex coagulation disorder will be associated with a
multitude of changes of specific coagulation tests compli-
cating their interpretation. In addition, indirect markers of
thrombin formation are indicators of events that have taken
place in the past, as active thrombin itself is cleared from
the circulation within minutes.161 The interpretation of
activation markers of coagulation and fibrinolysis is further
impeded by a high variation of their residence in circula-
tion.162 However, in other very common indications of
coagulation testing, such as the assessment of the bleeding
risk before elective surgeries or the risk of first or recurrent
thrombosis, the aforementioned advantages of global coag-
ulation tests do not apply. Although many studies cited in
this review measured specific coagulation parameters or
activation biomarkers in addition to global coagulation
testing, there is a paucity of studies directly comparing
global coagulation assays with the standard of care in terms
of clinical outcomes. A summary of specific advantages and
limitations of TEG/TEM, CWA, and TGA is provided
in ►Table 2.
Ongoing Research
Beyond the assay techniques presented so far, several other
global coagulation assays have been developed, either var-
iations of existing tests such as rheometric assays other than
TEG or TEM,163 or assays based on novel principles, some of
whichmight find a role in clinical routine in the future but at
the current stage of their development further research is
required. Among these methods are the thrombodynamics
assay, simultaneous measurement of thrombin and plasmin
generation, the observation of clot formation in flow perfu-
sion chambers, and artificial endothelium testing platforms.
The concept of global testing is here taking a bit forward the
process to evaluate the interaction between cellular and
plasmatic components with surfaces. In the thrombodynam-
ics assay spatial fibrin formation in plasma is monitored by
videomicroscopy after being triggered by immobilized TF,
with a clot initially forming on the activator and then
propagating into plasma (similar to the in vivo process).164
The temporospatial formation of thrombin can bemonitored
parallel to that of fibrin.165 Separation of the phases of
Table 2 Summary of relative advantages and limitations of thromboelastogram (TEG), thromboelastometry (TEM), clot waveform
analysis (CWA), and thrombin generation assay (TGA)
Assay Advantages Limitations
TEG/TEM • Point-of-care analysis
• Sensitive to abnormalities of fibrinolysis
• No detection of platelet-related disorders
• Poor standardization
CWA • Could be performed on routine coagulation analyzers • Low sensitivity toward mild thrombogenic
states
TGA • Highly adaptable to assess different thrombophilic states
• Comparably high degree of standardization and automation
• (Personnel-) and time-intensive
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activation and propagation is associated with a high sensi-
tivity of the assay to the presence of direct activators of
coagulation in plasma, such as circulating TF or activated
factor XI.166,167 Hypercoagulability measured using the
thrombodynamics assay has shown an association with
elevated D-dimer levels in patients with sepsis.168 Several
methods of simultaneous measurement of thrombin and
plasmin generation have been developed, in which coagula-
tion activation is triggered by TF, calcium, and phospholipids
or small amounts of exogenously added thrombin while
fibrinolysis activation is initiated by the addition of tissue-
type plasminogen activator. These methods have been eval-
uated in various patient populations with known hyper- and
hypocoagulable states and allow for the assessment of the
fibrinolytic system which is not captured by conventional
TGA.169–171 Flow chambers, in which the formation of plate-
let and fibrin clots can be observed by microscopy, are
increasingly used to monitor the combined processes of
platelet aggregation, thrombus formation, and coagulation
in human blood, allowing high-throughput measurement of
platelet activation processes, even in small blood samples.172
Several studies have demonstrated the potential of flow
perfusion chambers to detect prothrombotic changes in
blood.173–175
As mentioned earlier, TGA is designed to estimate the
thrombin concentration over time which is, however, not
the final endpoint of the coagulation process. The assess-
ment of fibrin formation by assays and analyzers able to
visualize the kinetic formation of fibrin clots is interesting.
Usually, clotting assays only report clotting time but many
other kinetic parameters may be relevant and have already
demonstrated their usefulness in the diagnosis and the
prognosis of different coagulation abnormalities.120 Re-
cently, the FibWave, a newly designed coagulation assay
based on the analysis of the kinetics of fibrin clot forma-
tion, assessed the overall coagulation process by measur-
ing changes in light absorbance that occur during clot
formation.176 This test appears to be sensitive, faster,
and less expensive than TGA in the assessment of antico-
agulant properties. Thanks to its ease of use, its possibility
to be implemented on routine coagulometers, and its
capacity to assess the whole coagulation process, the
FibWave could provide the clinicians with a global coagu-
lation test, sensitive at relevant threshold concentrations
with a reproducibility similar to the one observed on the
CT system.177
Viscoelastometric testing has been investigated for mon-
itoring as well as differentiating between classes of DOACs.
Dias et al found that in the TEG 5000 dabigatran increased
the R parameter of the citrated kaolin assay, and that
apixaban, rivaroxaban, and dabigatran increased the acti-
vated clotting time parameter of the citrated RapidTEG.178
Other groups found that the EXTEM clotting time could be
used to detect each of the four DOACs tested; however,
sensitivity was poor at drug concentrations within the
therapeutic ranges.179 Recently, the TEG 6s has been
assessed for the monitoring of DOACs.180 It was demon-
strated that the R parameter was the most sensitive and
correlated with the DOAC concentration when assessed via
the specific cartridge for factor Xa or thrombin inhibi-
tors.180 The predictive value of this assay was reported to
be very high (>98%), which is particularly important in
emergency situations.
A novel approach to overcome the limitations of conven-
tional coagulation activation marker measurement and, in
some sense, an in vivo counterpart of in vitro thrombin
generation by TGA is themeasurement of active key enzymes
of hemostasis. Using highly specific aptamers that do not
cross-react with the inactive proenzymes, as capture ligands,
enzyme capture assays have been developed that allow
direct quantification of free thrombin and APC in human
plasma in the picomolar range.181,182 These oligonucleotide-
based enzyme capture assays have been shown to be able to
measure in vivo thrombin and subsequent APC generation in
real-world conditions of coagulation activation such as sur-
gical trauma or septic shock.183,184 In addition, these assays
have been applied in human models of venous stasis or
coagulation activation induced by activated factor
VII.185,186 The latter approach, termed stimulated hemosta-
sis activity pattern analysis (SHAPE), revealed distinctive
reaction patterns of pro- and anticoagulant responses in
carriers and noncarriers of the thrombophilia FVL and pro-
thrombin 20210G>A mutations and in FVL mutation car-
riers with and without a history VTE.187 While these data
have shown the ability of the SHAPE approach to assess the
functionality of the thrombin–PC pathway, its ability to
predict first or recurrent VTE in the future is still under
investigation.
As a final remark, in the current digital era, real-time
remote viewing of any of the here presented global methods
would be of interest for clinicians, as it will permit to directly
monitor the results in real-time while facing the patients.
Time Capsule
• Since the first introduction of global coagulation assays in
the 1950s several commercially available assays have
found broad use, including thromboelastography and
the thrombin generation assay.
• The advantages of these assays lie in the assessment of
simultaneous pro- and anticoagulant changes occurring,
e.g., in complex coagulation disorders or under anticoag-
ulant treatment.
• Global thrombophilia screening is needed to assess the
thrombogenicity before the induction of some thrombo-
genic therapies. Global coagulations tests are candidate
assays for this screening.
• Standardization and automation are key factors to
improve global coagulation assays. Automated thrombin
generation is promising regarding screening of both
hemorrhagic and thrombotic tendencies.
• A perfect in vitro simulation of hemostasis might remain
an impossible task as factors outside of the coagulation
and fibrinolysis system contribute to an increased risk of
bleeding or thrombosis.
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